Skip to main content
Premium Trial:

Request an Annual Quote

Jennine Cannizzo and Peter Natale

Premium

Jennine Cannizzo has been named vice president of marketing for Artel, the company said on June 10.

Cannizzo joins Artel from IDEXX Laboratories, where she served as vice president of worldwide customer support. She holds a BS in biology from Loyola University in Chicago.

Artel designs, manufactures, and markets photometric-based analytical instruments and software for pharmaceutical, clinical diagnostic, biotechnology, forensic, food safety, and other laboratory quality assurance applications. The company’s newest product is the MVS multi-channel volumetric verification system for calibrating automated liquid handlers with as many as 96 tips.


Peter Natale is the new chief information officer at Becton Dickinson, the company said last week.

Natale will report to John Considine, executive vice president and chief financial officer at BD, and will have overall responsibility for BD’s global IT operations, the company said.

Natale joins BD from General Electric, where he most recently served as the Americas IT leader for GE Consumer and Industrial, a $9 billion business unit. Prior to this, he was CIO for GE’s Electrical Products and Power Equipment business. He is a graduate of the University of Connecticut.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.